v3.26.3
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Increase (decrease) in related party accounts receivable [1] $ 71,839 $ 63,199
Increase (decrease) in related party deferred revenue [2] (24,107) 17,398
Deferred other income [3] (11,966) (11,966)
Pathos AI [Member]    
Increase (decrease) in related party accounts receivable 5,664 2,352
Increase (decrease) in related party deferred revenue (3,835) 19,918
Related party preferred stock 17,500  
S B Tempus Corp [Member]    
Increase (decrease) in related party accounts receivable 145 108
Increase (decrease) in related party deferred revenue (6,235) (18,737)
Deferred other income $ (11,966) $ (11,966)
[1] Includes increase in related party accounts receivable from Pathos AI, Inc. of $5,664 and $2,352 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. Includes increase in related party accounts receivable from SB Tempus Corp. of $145 and $108 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture.
[2] Includes decrease in related party deferred revenue from Pathos AI, Inc. of $3,835 for the nine months ended September 30, 2026. Includes increase in related party deferred revenue from Pathos AI, Inc. of $19,918 for the nine months ended September 30, 2025, respectively. Refer to Note 16, Related Parties. Also includes decrease in related party deferred revenue from SB Tempus Corp. of $6,235 and $18,737 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture.
[3] Includes decrease in related party deferred other income from SB Tempus Corp. of $11,966 for each of the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint Venture.